^
Association details:
| Biomarker: | MUTYH Q324H |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | carboplatin (Tubulin polymerization promoter) + pemetrexed (Thymidylate synthase inhibitor, THF dehydrogenase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Genetic Investigation of Polymorphic OGG1 and MUTYH Genes Towards Increased Susceptibility in Lung Adenocarcinoma and its Impact on Overall Survival of Lung Cancer Patients Treated with Platinum Based Chemotherapy
Excerpt:
...326 lung cancer cases...Stratified analysis for chemotherapeutic drugs revealed administration of Cisplatin/Carboplatin + Pemtrexed...Whereas, MUTYH Gln324His showed a smaller survival for mutant genotype (CC) (MST CC vs. GG: 4.0 vs. 9.4, p = 0.05; HR = 1.75, p = 0.26).
DOI:
10.1007/s12253-017-0372-6
